Radiolabeled α(ν)β3 integrin antagonists: A new class of tracers for tumor targeting

Journal of Nuclear Medicine

Volumn 40, Issue 6, 1999, Pages 1061-1071

  Haubner, Roland ^a   Wester, Hans Jürgen ^b   Reuning, Ute ^b   Senekowitsch Schmidtke, Reingard ^b   Diefenbach, Beate ^b   Kessler, Horst ^b   Stöcklin, Gerhard ^b   Schwaiger, Markus ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

125I labeling; Alpha(v)beta(3 antagonists; Integrins; ; RGD peptides; Tumor targeting

Indexed keywords

INTEGRIN; TRACER; DIAGNOSTIC AGENT; OLIGOPEPTIDE; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BREAST CARCINOMA; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; PRIORITY JOURNAL; RADIOIODINATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; BIOASSAY; COMPARATIVE STUDY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; SCINTISCANNING;

ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BIOLOGICAL ASSAY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMMUNOHISTOCHEMISTRY; INTEGRINS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; OSTEOSARCOMA;

EID: 0032587186     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reubi JC. Relevance of somatostatin receptors and other peptide receptors in pathology.Endocr Pathol. 1997;8:11-20.
2. Albelda SM. Biology of disease: role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest. 1993;68:4-17.
3. Glukhova M, Deugnier MA, Thiery JR Tumor progression: the role of cadherins and integrins. Mol Med Today. 1995;1:84-89.
4. v-integrins in tumour progression and metastasis. Cancer Biol. 1996;7:129-138.
5. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990;4:2868-2880.
6. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
7. Ojima I, Chakravarty S, Dong Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg Med Chem. 1995;3:337-360.
8. Chorev M, Dresner-Pollak R, Eshel Y, Rosenblatt M. Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade. Biopolym. (Pep Sci.) 1995;37:367-375.
9. 3 for angiogenesis. Science. 1994;264:569-571.
10. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
11. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
12. 3 subunit with tumor progression. Cancer Res. 1990;5:6757-6764.
13. v gene expression in human melanoma tumorigenicity. J Clin Invest. 1992;89:2018-2022.
14. 5 integrins by human lung carcinoma cells of different histotypes. Exp Cell Res. 1994;210:113-122.
15. 1 in cancer cell adhesion to interleukin-1-treated endothelial cells. Eur J Cancer. 1994;30:2151-2158.
16. 3 integrin. J Clin Invest. 1991;88:1924-1932.
17. 3 to adhere to lymph node vitronectin. J Clin Invest. 1992;90:1406-1413.
18. 5 integrins with tumor invasiveness. Pathol Int. 1995;45:493-500.
19. 3 integrin for a new cancer therapy. Angew Chem Int Ed Engl. 1997;36:1374-1389.
20. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44:517-518.
21. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991;291:50-54.
22. Gurrath M, Müller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem. 1992;210:911-921.
23. 1 integrins. J Biol Chem. 1994;269:20233-20238.
24. 3 antagonists. J Am Chem Soc. 1996;118: 7461-7472.
25. Stöcklin G, Wester HJ. Strategies for radioligand development. Peptides for tumor targeting. In: Gulyas B, Müller-Gärtner HW, eds. Positron Emission Tomography: A Critical Assessment of Recent Trends. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1998:57-90.
26. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl Med Biol. 1997;24:485-498.
27. König W, Geiger G. A new method for the synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazoles as additives. Chem Ber. 1970;103:788-798.
28. α-9-fluorenylmethyloxy-carbonyl amino acids bearing tert-butyl side chain pretection, Int J Pept Protein Res. 1980;15:59-66.
29. Yatohgo T, Kashiwagi H, Izumi M, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct. 1988;13:281-292.
30. Kazal LA, Ansel S, Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycin. Proc Soc Exp Biol Med. 1963;113:989-994.
31. Smith JW, Cheresh DA. The Arg-Gly-Asp binding domain of the vitronectin receptor photoaffinity cross-linking implicates amino acid residues 61-203 of the β-subunit. J Biol Chem. 1981;263:8726-8738.
32. Mitjans FC, Sander D, Adán J, et al. An anti-alpha-v integrin antibody that blocks integrin function inhibiting the development of a human melanoma in nude mice. J Cell Sci. 1995;108:2825-2838.
33. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987;262:7703-7711.
34. Pytela R, Ginsberg MH, Pierschbacher MD, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science. 1986;231:1559-1562.
35. Senekowitsch R, Reidel G, Möllenstädt S, Kriegel H, Pabst HW. Curative radioimmunotherapy of human mammary carcinoma xenografts with iodine-131-labeled monoclonal antibodies. J Nucl Med. 1989;30:531-537.
36. v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.
37. Folkman J. Addressing tumor blood vessels. Nat Bioiechnol. 1997;15:510.
38. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
39. Haubner R, Wester HJ, Senekowitsch-Schmidtke R, et al. Radio-labeled RGD-peptides as tracer for tumor targeting and therapy control [in German] [abstract]. Nuklearmedizin. 1997;36:A93.
40. Haubner R, Wester HJ, Senekowitsch-Schmidtke R, et al. Radiolabeled RGD-peptides: a new class of tracers for tumor targeting [abstract]. J Nucl Med. 1997;38:190P.